Evidence map›Paper›PMID 34260297›Full record

Trial reportThe British journal of radiology2021

Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.

Fuli Wang, Aizhong Qu, Yinping Sun, Jifeng Zhang, Benzun Wei, Yong Cui, Xiao Liu, Wei Tian, Yan Li

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Fuli WangShandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Aizhong QuShandong Cancer Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yinping SunDepartment of Oncology,Zibo Central Hospital, Shandong University, Zibo, China.
Jifeng ZhangDepartment of Oncology,Zibo Central Hospital, Shandong University, Zibo, China.
Benzun WeiDepartment of General Surgery, Zibo Central Hospital, Shandong University, Zibo, China.
Yong CuiDepartment of Oncology, Shouguang People's Hospital affiliated to Weifang Medical College, Shouguang, China.
Xiao LiuDepartment of Oncology,Zibo Central Hospital, Shandong University, Zibo, China.
Wei TianDepartment of Oncology,Zibo Central Hospital, Shandong University, Zibo, China.
Yan LiDepartment of Oncology, Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Central Hospital of Zibo · CNShandong University · CNShandong Tumor Hospital · CNWeifang People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to compare the clinical efficacy of neoadjuvant chemoradiotherapy (NACRT) combined with postoperative adjuvant XELOX (Oxaliplatin +Capecitabine) chemotherapy and postoperative adjuvant chemotherapy (ACT) with XELOX for local advanced gastric cancer (LAGC).

methodsIn this prospectively randomized trial, we investigated the effect of NACRT combined with postoperative ACT for LAGC. 60 patients were randomly divided into NACRT group and ACT group, with 30 patients in each group. Patients in NACRT group were given three-dimensional conformal radiotherapy (45 Gy/1.8 Gy/f) accompanied by synchronous XELOX of two cycles, followed by surgery, and then postoperative adjuvant XELOX chemotherapy of four cycles was performed. Patients in ACT group received surgery in advance, and then XELOX chemotherapy of six cycles was given.

resultsThe objective response rate of NACRT was 76.7%. The overall incidence of postoperative complications in NACRT group was not significantly different from that in ACT group (23.1%

conclusionsNACRT combined with postoperative adjuvant XELOX chemotherapy can improve R0 resection rate, reduce loco-regional recurrence, prolong PFS and FFLP without increasing the incidence of postoperative complications in patients with LAGC. ADVANCES IN KNOWLEDGE: Compared with postoperative adjuvant chemotherapy, locally advanced gastric cancer patients may benefit from neoadjuvant chemoradiotherapy, and toxicity associated with chemoradiotherapy was tolerant and manageable.

Indexed as

Radiotherapy, ConformalAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapy, AdjuvantChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessOxaloacetatesPostoperative PeriodProspective StudiesStomach NeoplasmsTreatment OutcomeCapecitabineOxaloacetates

Identifiers

PMID34260297
PMCPMC8764914
OpenAlexW3180867425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.